News Column

Protea Biosciences Group, Inc. Files SEC Form SC 13D, General Statement of Acquisition of Beneficial Ownership [Amend] (Aug. 25, 2014)

September 8, 2014

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Protea Biosciences Group, Inc. (Form SC 13D) was posted on August 25, 2014.

The SIC code for this company is 2834, Pharmaceutical Preparations.

There was one document filed with this form. The SEC file number is 0001144204-14-052226.

The contact information for this company is 955 HARTMAN RUN ROAD, MORGANTOWN WV 26505, 304 292-2226.

Our editors provided additional information about Form SC 13D: This Schedule discloses beneficial ownership of certain registered equity securities. Any person or group of persons who acquire a beneficial ownership of more than 5% of a class of registered equity securities of certain issuers must file a Schedule 13D reporting such acquisition together with certain other information within ten days after such acquisition. Moreover, any material changes in the facts set forth in the Schedule generally precipitates a duty to promptly file an amendment on Schedule 13D. The Commission's rules define the term "beneficial owner" to be any person who directly or indirectly shares voting power or investment power (the power to sell the security).

A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

For additional information on this SEC filing see:

Keywords for this news article include: Biotechnology Company, Chemicals, Chemistry, Pharmaceutical Preparations, Protea Biosciences, Protea Biosciences Group Inc., SEC Filing.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Pharma Business Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters